抗胆碱能药物治疗过度活跃膀胱试验中安慰剂导入期与治疗效应量及脱落风险无关:一项实证评价
该研究基于已发表的系统综述,纳入96项抗胆碱能药物治疗过度活跃膀胱的随机试验,其中37项有安慰剂导入期、59项无导入期,采用荟萃分析混合效应模型比较两组在疗效和脱落等结局上的差异。结果显示,有安慰剂导入期与无导入期的试验在所有结局的效应估计值上均无重要差异,调整混杂因素后结论不变。提示安慰剂导入期的预期获益在本样本中未观察到。
要点
- 在抗胆碱能药物治疗过度活跃膀胱的随机试验中,安慰剂导入期与无导入期相比,各结局的效应估计值无重要差异。
- 调整潜在混杂因素后,安慰剂导入期与治疗效应量及脱落风险无关的结论未发生实质性改变。
- 未来设计抗胆碱能药物试验时采用更务实的意图,可能产生更直接指导临床决策的证据。
核心结论
- 在本样本的抗胆碱能药物治疗过度活跃膀胱随机试验中,未观察到安慰剂导入期的预期获益。
研究设计与样本
- 研究从一项已发表的系统综述中识别抗胆碱能药物治疗过度活跃膀胱的随机试验。
- 共纳入96项符合标准的试验:59项无导入期(包括筛查期或洗脱期),37项有安慰剂导入期,无药物导入期试验。
- 采用荟萃分析混合效应模型评估导入期类型与效应估计值大小的关联,并调整潜在混杂因素。
主要发现
- 有安慰剂导入期与无导入期的试验在所有结局的效应估计值大小上均无重要差异。
- 调整混杂变量后,效应估计值未发生实质性改变。
临床怎么用
- 设计抗胆碱能药物未来试验时采用更务实的意图,可能产生更直接 informing 临床决策的证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We aimed to explore the impact of run-in periods on the magnitude of treatment effect and the risk of attrition in a sample of randomized trials. STUDY DESIGN AND SETTING: We identified randomized trials from a published systematic review examining the effects of anticholinergics for the treatment of overactive bladders. We fitted meta-analytic mixed-effects models to assess whether the type of run-in (placebo run-in vs. no run-in) was associated with the magnitude of the effect estimates for the following outcomes: the number of voids per day, number of leakages per day, presence of dry mouth, cure/improvement, patient withdrawal from the trial, compliance with the trial protocol, and/or adherence to study drug. We adjusted for potential confounders. RESULTS: A total of 96 trials met the eligibility criteria; 59 trials had no run-in (which included those with a screening or withdrawal period), 37 trials had a placebo run-in, and no trials had a drug run-in. The magnitude of the effect estimates for all outcomes did not importantly differ between trials with a placebo run-in and trials with no run-in. Adjustment for the confounding variables did not materially change the estimates. CONCLUSION: The hypothesized benefits of placebo run-in periods were not observed in our sample of anticholinergic randomized trials for the treatment of overactive bladders. Designing future trials of anticholinergics with more pragmatic intentions is likely to result in evidence that more directly informs clinical decision-making.
引用
- Karahalios A, Herbison GP, McKenzie JE, et al. Placebo run-in periods in anticholinergic trials are not associated with treatment effect size or risk of attrition: an empirical evaluation. J Clin Epidemiol. 2020. PMID: 32531264. doi:10.1016/j.jclinepi.2020.05.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。